AxoGen, Inc. (NASDAQ:AXGN) is Perkins Capital Management Inc.’s 5th Largest Position

Perkins Capital Management Inc. lowered its position in AxoGen, Inc. (NASDAQ:AXGN) by 2.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 283,399 shares of the medical equipment provider’s stock after selling 5,950 shares during the quarter. AxoGen comprises approximately 3.7% of Perkins Capital Management Inc.’s portfolio, making the stock its 5th largest holding. Perkins Capital Management Inc.’s holdings in AxoGen were worth $3,973,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in AxoGen during the third quarter valued at approximately $56,000. Koss Olinger Consulting LLC purchased a new position in AxoGen in the second quarter worth $75,000. Lazard Asset Management LLC increased its stake in AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock valued at $93,000 after acquiring an additional 2,671 shares during the last quarter. Acadian Asset Management LLC bought a new position in AxoGen in the second quarter valued at $125,000. Finally, BNP Paribas Financial Markets increased its stake in AxoGen by 8.6% in the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after acquiring an additional 1,651 shares during the last quarter. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Trading Up 2.5 %

Shares of AXGN stock opened at $15.33 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.51 and a quick ratio of 2.32. The business has a 50-day moving average of $13.81 and a 200 day moving average of $10.05. The stock has a market capitalization of $671.91 million, a PE ratio of -40.34 and a beta of 1.13. AxoGen, Inc. has a 1-year low of $4.16 and a 1-year high of $15.90.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $47.91 million during the quarter, compared to analyst estimates of $43.27 million. AxoGen had a negative net margin of 9.53% and a negative return on equity of 17.30%. As a group, sell-side analysts anticipate that AxoGen, Inc. will post -0.33 earnings per share for the current year.

Analyst Upgrades and Downgrades

AXGN has been the subject of several research analyst reports. JMP Securities lifted their price target on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research note on Friday, August 9th. StockNews.com raised AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $15.00.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.